Primary source: Safety monitoring and information
A safety alert was published due to the usage of sucralose instead of the intended thaumatin in the sweetener formulation of affected products.
The incorrect sweetener may pose safety concerns for consumers, requiring immediate regulatory attention and reinforcing the importance of compliance with labeling and formulation standards.
Monitoring of the affected batches will be essential to ensure regulatory compliance and consumer safety, alongside implementation of any necessary recall procedures.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Monitoring of the affected batches will be essential to ensure regulatory compliance and consumer safety, alongside implementation of any necessary recall procedures.
TGA has issued a safety alert regarding the use of an incorrect sweetener (sucralose) in Nutra-life Magnesium and Sleep Products and Musashi Pre Workout Chewables, impacting product safety.
What changed: A safety alert was published due to the usage of sucralose instead of the intended thaumatin in the sweetener formulation of affected products.
Why it matters: The incorrect sweetener may pose safety concerns for consumers, requiring immediate regulatory attention and reinforcing the importance of compliance with labeling and formulation standards.
Practical implication: Monitoring of the affected batches will be essential to ensure regulatory compliance and consumer safety, alongside implementation of any necessary recall procedures.
Published from the regulator source ingestion pipeline after PV impact triage.
Review and update the labeling and training materials to include new user manual information for the Aspire Active Air 8 Pressure Care Mattress.
Healthcare providers should quarantine all impacted epidural kits and remove any sodium chloride ampules affected by this recall, implementing corrective actions per FDA guidance.
Review the updated guidance to incorporate the new compliance procedures starting from 1 January 2026, specifically regarding the electronic submission process.
Marketing authorization holders must implement processes to ensure timely submissions of required data within the defined 15 and 30 calendar day timelines, including details of the Qualified Person responsible for Pharmacovigilance and the submission of Pharmacovigilance System Master File information.
